[go: up one dir, main page]

NO20065982L - Inhibition of HIV-1 Replication by Interrupting Processes of the Copper Spacer Peptide 1 Protein - Google Patents

Inhibition of HIV-1 Replication by Interrupting Processes of the Copper Spacer Peptide 1 Protein

Info

Publication number
NO20065982L
NO20065982L NO20065982A NO20065982A NO20065982L NO 20065982 L NO20065982 L NO 20065982L NO 20065982 A NO20065982 A NO 20065982A NO 20065982 A NO20065982 A NO 20065982A NO 20065982 L NO20065982 L NO 20065982L
Authority
NO
Norway
Prior art keywords
gag
protein
inhibition
hiv
replication
Prior art date
Application number
NO20065982A
Other languages
Norwegian (no)
Inventor
Carl T Wild
Karl Salzwedel
Feng Li
Graham P Allaway
Eric O Freed
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/851,637 external-priority patent/US7537765B2/en
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Publication of NO20065982L publication Critical patent/NO20065982L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C07K16/1143—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)

Abstract

Inhibisjon av HIV- I -replikasjon ved å nedbryte prosessen til det virale Gag (KA) protein (p24) fra CA-spacer peptid- 1 (SP1) proteinforløper (p25), er beskrevet. Aminosyresekvenser inneholdende en mutasjon i Gag p25-proteinet med mutasjonen resulterer i en reduksjon i inhibisjon av bearbeidingen av p25 til p24 ved dimetylsuksinyl betulinsyre eller dimetylsuksinylbetulin, polynukleotider som koder slike muterte sekvenser, og antistoffer som selektivt binder slike muterte sekvenser er også inkludert. Inhibisjonsfremgangsmåter, inhiberende forbindelser og fremgangsmåter for oppdagelse av inhiberende forbindelser som målretter proteolytisk prosesser i HIV-Gag-protein er inkludert. I en utførelsesform inhiberer slike forbindelser HIV-proteaseenzymets interaksjonen med Gag ved å binde til Gag i stedet for til proteaseenzymet. I en annen utførelsesform kan virus eller rekombinante proteiner inneholdende mutasjoner i det Gag-proteolytiske kløvingssetets område, anvendes i screeningsanalyser for å identifisere forbindelser som målsøker proteolytisk prosess.Inhibition of HIV-I replication by disrupting the process of the viral Gag (KA) protein (p24) from CA spacer peptide-1 (SP1) protein precursor (p25) is described. Amino acid sequences containing a mutation in the Gag p25 protein with the mutation result in a reduction in inhibition of the processing of p25 to p24 by dimethylsuccinyl betulinic acid or dimethylsuccinylbetulin, polynucleotides encoding such mutated sequences, and antibodies which selectively bind sequences. Inhibition methods, inhibitory compounds and methods for detecting inhibitory compounds that target proteolytic processes in HIV-Gag protein are included. In one embodiment, such compounds inhibit the interaction of the HIV protease enzyme with Gag by binding to Gag instead of the protease enzyme. In another embodiment, viruses or recombinant proteins containing mutations in the region of the Gag proteolytic cleavage site can be used in screening assays to identify compounds targeting the proteolytic process.

NO20065982A 2004-05-24 2006-12-22 Inhibition of HIV-1 Replication by Interrupting Processes of the Copper Spacer Peptide 1 Protein NO20065982L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/851,637 US7537765B2 (en) 2003-01-29 2004-05-24 Inhibition of HIV-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein
US65396105P 2005-02-17 2005-02-17
PCT/US2005/018331 WO2005113059A2 (en) 2004-05-24 2005-05-24 Disruption of the processing of the viral capsid-spacer peptide 1 protein

Publications (1)

Publication Number Publication Date
NO20065982L true NO20065982L (en) 2007-02-01

Family

ID=35428872

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065982A NO20065982L (en) 2004-05-24 2006-12-22 Inhibition of HIV-1 Replication by Interrupting Processes of the Copper Spacer Peptide 1 Protein

Country Status (9)

Country Link
EP (1) EP1758640A4 (en)
JP (1) JP2008504808A (en)
AU (1) AU2005245506A1 (en)
BR (1) BRPI0511514A (en)
CA (1) CA2568248A1 (en)
IL (1) IL179494A0 (en)
MX (1) MXPA06013698A (en)
NO (1) NO20065982L (en)
WO (1) WO2005113059A2 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679828A (en) * 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
WO2003004641A1 (en) * 2001-07-06 2003-01-16 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Process for producing human thrombin by gene modification technique
EP1425380A4 (en) * 2001-08-15 2004-12-22 Univ California RETROVIRUS ISOLATED FROM COAT HISTIOCYTES

Also Published As

Publication number Publication date
CA2568248A1 (en) 2005-12-01
AU2005245506A1 (en) 2005-12-01
BRPI0511514A (en) 2008-08-05
JP2008504808A (en) 2008-02-21
EP1758640A2 (en) 2007-03-07
WO2005113059A3 (en) 2007-02-15
MXPA06013698A (en) 2007-08-15
IL179494A0 (en) 2007-05-15
EP1758640A4 (en) 2009-06-03
WO2005113059A2 (en) 2005-12-01

Similar Documents

Publication Publication Date Title
Franchini et al. Sequence of simian immunodeficiency virus and its relationship to the human immunodeficiency viruses
Tözsér et al. Comparison of the HIV-1 and HIV-2 proteinases using oligopeptide substrates representing cleavage sites in Gag and Gag-Pol polyproteins
Altfeld et al. Enhanced detection of human immunodeficiency virus type 1-specific T-cell responses to highly variable regions by using peptides based on autologous virus sequences
Svarovskaia et al. Azido-containing diketo acid derivatives inhibit human immunodeficiency virus type 1 integrase in vivo and influence the frequency of deletions at two-long-terminal-repeat-circle junctions
Álvarez et al. HIV protease cleaves poly (A)-binding protein
Lee et al. Identification and characterization of virus assembly intermediate complexes in HIV-1-infected CD4+ T cells
Li et al. Rapid reversion of sequence polymorphisms dominates early human immunodeficiency virus type 1 evolution
Tomasselli et al. Actin, troponin C, Alzheimer amyloid precursor protein and pro-interleukin 1 beta as substrates of the protease from human immunodeficiency virus
Melamed et al. The conserved carboxy terminus of the capsid domain of human immunodeficiency virus type 1 gag protein is important for virion assembly and release
WO2004069166A3 (en) Inhibition of hiv-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein
Stansell et al. Gp120 on HIV-1 virions lacks O-linked carbohydrate
Ott et al. Elimination of protease activity restores efficient virion production to a human immunodeficiency virus type 1 nucleocapsid deletion mutant
Schneider et al. Development of HIV fusion inhibitors
Zhirnov et al. Interaction of influenza A virus M1 matrix protein with caspases
Zhang et al. Poly (A) binding protein, C-terminally truncated by the hepatitis A virus proteinase 3C, inhibits viral translation
Hizi et al. Analysis of gag proteins from mouse mammary tumor virus
Ludwig et al. Importance of protease cleavage sites within and flanking human immunodeficiency virus type 1 transframe protein p6* for spatiotemporal regulation of protease activation
NO20065982L (en) Inhibition of HIV-1 Replication by Interrupting Processes of the Copper Spacer Peptide 1 Protein
Rumlová et al. Specific in vitro cleavage of Mason–Pfizer monkey virus capsid protein: evidence for a potential role of retroviral protease in early stages of infection
Zábranský et al. Three active forms of aspartic proteinase from Mason–Pfizer monkey virus
Beck et al. Molecular basis for the relative substrate specificity of human immunodeficiency virus type 1 and feline immunodeficiency virus proteases
Hilton et al. An assay to monitor HIV-1 protease activity for the identification of novel inhibitors in T-cells
Ndlovu et al. Envelope characteristics in individuals who developed neutralizing antibodies targeting different epitopes in HIV-1 subtype C infection
Zawahir et al. Inhibition of HIV-1 integrase activity by synthetic peptides derived from the HIV-1 HXB2 Pol region of the viral genome
Fournier et al. The HIV-1 Nef protein enhances the affinity of reverse transcriptase for RNA in vitro

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application